USD 2.75
(0.37%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 27.34 Million USD | -6.49% |
2022 | 29.24 Million USD | 1227.52% |
2021 | 2.2 Million USD | 110.71% |
2020 | 1.04 Million USD | 965.27% |
2019 | 98.14 Thousand USD | -91.44% |
2018 | 1.14 Million USD | 345.3% |
2017 | 257.48 Thousand USD | 299.8% |
2016 | 64.4 Thousand USD | -90.43% |
2015 | 673.26 Thousand USD | 369.42% |
2014 | 143.42 Thousand USD | 359.1% |
2013 | 31.24 Thousand USD | -76.82% |
2012 | 134.79 Thousand USD | 26.64% |
2011 | 106.43 Thousand USD | -48.74% |
2010 | 207.62 Thousand USD | 85.19% |
2009 | 112.11 Thousand USD | 2129.39% |
2008 | 5029.00 USD | -66.24% |
2007 | 14.89 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 31.89 Million USD | 16.64% |
2024 Q2 | 29.3 Million USD | -8.14% |
2023 Q1 | 26.99 Million USD | -7.7% |
2023 Q2 | 28.41 Million USD | 5.26% |
2023 FY | 27.34 Million USD | -6.49% |
2023 Q4 | 27.34 Million USD | -1.1% |
2023 Q3 | 27.65 Million USD | -2.67% |
2022 Q2 | 41.99 Million USD | 213.15% |
2022 FY | 29.24 Million USD | 1227.52% |
2022 Q3 | 40.86 Million USD | -2.68% |
2022 Q1 | 13.4 Million USD | 508.72% |
2022 Q4 | 29.24 Million USD | -28.44% |
2021 FY | 2.2 Million USD | 110.71% |
2021 Q1 | 1.85 Million USD | 77.76% |
2021 Q3 | 2.5 Million USD | 37.69% |
2021 Q2 | 1.81 Million USD | -2.23% |
2021 Q4 | 2.2 Million USD | -11.95% |
2020 Q1 | 63.68 Thousand USD | -35.11% |
2020 FY | 1.04 Million USD | 965.27% |
2020 Q3 | 550.52 Thousand USD | 297.44% |
2020 Q4 | 1.04 Million USD | 89.91% |
2020 Q2 | 138.51 Thousand USD | 117.49% |
2019 FY | 98.14 Thousand USD | -91.44% |
2019 Q3 | 146.33 Thousand USD | 33.77% |
2019 Q2 | 109.38 Thousand USD | -91.23% |
2019 Q1 | 1.24 Million USD | 8.75% |
2019 Q4 | 98.14 Thousand USD | -32.93% |
2018 Q2 | 1.17 Million USD | 16.76% |
2018 Q3 | 1.1 Million USD | -5.64% |
2018 FY | 1.14 Million USD | 345.3% |
2018 Q1 | 1 Million USD | 289.28% |
2018 Q4 | 1.14 Million USD | 3.82% |
2017 Q1 | 23.4 Thousand USD | -63.65% |
2017 Q4 | 257.48 Thousand USD | 0.58% |
2017 Q2 | 164.33 Thousand USD | 602.02% |
2017 FY | 257.48 Thousand USD | 299.8% |
2017 Q3 | 256 Thousand USD | 55.78% |
2016 Q1 | 830.6 Thousand USD | 23.37% |
2016 FY | 64.4 Thousand USD | -90.43% |
2016 Q4 | 64.4 Thousand USD | -89.25% |
2016 Q3 | 599.32 Thousand USD | -9.94% |
2016 Q2 | 665.44 Thousand USD | -19.88% |
2015 FY | 673.26 Thousand USD | 369.42% |
2015 Q4 | 673.26 Thousand USD | 392.74% |
2015 Q2 | 170.74 Thousand USD | 14.83% |
2015 Q3 | 136.63 Thousand USD | -19.98% |
2015 Q1 | 148.7 Thousand USD | 3.68% |
2014 Q2 | 44.05 Thousand USD | -38.65% |
2014 FY | 143.42 Thousand USD | 359.1% |
2014 Q1 | 71.8 Thousand USD | 129.85% |
2014 Q4 | 143.42 Thousand USD | -20.44% |
2014 Q3 | 180.27 Thousand USD | 309.24% |
2013 Q4 | 31.24 Thousand USD | -56.37% |
2013 Q3 | 71.6 Thousand USD | -55.47% |
2013 Q2 | 160.81 Thousand USD | -37.9% |
2013 Q1 | 258.95 Thousand USD | 92.11% |
2013 FY | 31.24 Thousand USD | -76.82% |
2012 Q4 | 134.79 Thousand USD | -49.71% |
2012 Q1 | 84.18 Thousand USD | -20.91% |
2012 Q2 | 108.98 Thousand USD | 29.47% |
2012 Q3 | 268.04 Thousand USD | 145.94% |
2012 FY | 134.79 Thousand USD | 26.64% |
2011 Q1 | 159.33 Thousand USD | -23.26% |
2011 Q3 | 224.21 Thousand USD | 57.33% |
2011 FY | 106.43 Thousand USD | -48.74% |
2011 Q4 | 106.43 Thousand USD | -52.53% |
2011 Q2 | 142.51 Thousand USD | -10.56% |
2010 Q3 | 108.14 Thousand USD | 563.85% |
2010 Q4 | 207.62 Thousand USD | 91.98% |
2010 Q2 | 16.29 Thousand USD | -44.1% |
2010 FY | 207.62 Thousand USD | 85.19% |
2010 Q1 | 29.14 Thousand USD | 0.0% |
2009 FY | 112.11 Thousand USD | 2129.39% |
2009 Q3 | 179.84 Thousand USD | 28133.12% |
2009 Q2 | 637.00 USD | 0.16% |
2009 Q1 | 636.00 USD | -48.29% |
2008 Q1 | 5291.00 USD | 8.42% |
2008 FY | 5029.00 USD | -66.24% |
2008 Q3 | 2391.00 USD | -52.46% |
2008 Q4 | 1230.00 USD | -48.56% |
2008 Q2 | 5029.00 USD | -4.95% |
2007 Q2 | - USD | 0.0% |
2007 Q3 | 7895.00 USD | 0.0% |
2007 FY | 14.89 Thousand USD | 0.0% |
2007 Q4 | 4880.00 USD | -38.19% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Theratechnologies Inc. | 77.76 Million USD | 64.836% |
Harrow Health, Inc. | 311.75 Million USD | 91.228% |
Dynavax Technologies Corporation | 997.09 Million USD | 97.257% |
Biofrontera Inc. | 27.93 Million USD | 2.095% |
Cronos Group Inc. | 1.13 Billion USD | 97.589% |
Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -83.623% |
Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 94.195% |
Kala Pharmaceuticals, Inc. | 55.94 Million USD | 51.122% |
RedHill Biopharma Ltd. | 23.04 Million USD | -18.657% |
Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 66.559% |
Radius Health, Inc. | 1.71 Billion USD | 98.406% |
Universe Pharmaceuticals INC | 53.28 Million USD | 48.68% |
DURECT Corporation | 45.18 Million USD | 39.483% |
ProPhase Labs, Inc. | 91.92 Million USD | 70.251% |
Safety Shot Inc | 12.7 Million USD | -115.175% |
Phibro Animal Health Corporation | 982.18 Million USD | 97.216% |
China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -18.247% |
Alvotech | 950.09 Million USD | 97.122% |
Assertio Holdings, Inc. | 286.41 Million USD | 90.452% |
Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.059% |
Rockwell Medical, Inc. | 52.17 Million USD | 47.584% |
Procaps Group S.A. | 460.18 Million USD | 94.057% |
Intra-Cellular Therapies, Inc. | 728.29 Million USD | 96.245% |
SCYNEXIS, Inc. | 128.41 Million USD | 78.704% |
Aytu BioPharma, Inc. | 118.09 Million USD | 76.843% |
Viatris Inc. | 47.68 Billion USD | 99.943% |
OptiNose, Inc. | 107.72 Million USD | 74.615% |
SIGA Technologies, Inc. | 254.83 Million USD | 89.269% |
Tilray Brands, Inc. | 4.33 Billion USD | 99.369% |
PetIQ, Inc. | 868.22 Million USD | 96.85% |
Sunshine Biopharma, Inc. | 27.34 Million USD | 0.0% |
Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.159% |
Guardion Health Sciences, Inc. | 11.91 Million USD | -129.456% |
Alimera Sciences, Inc. | 153.52 Million USD | 82.187% |
Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 97.608% |
Silver Spike Investment Corp. | 88.57 Million USD | 69.126% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -359.479% |
Organogenesis Holdings Inc. | 460.02 Million USD | 94.055% |
Journey Medical Corporation | 76.84 Million USD | 64.415% |
Petros Pharmaceuticals, Inc. | 33.79 Million USD | 19.082% |
Alpha Teknova, Inc. | 128.58 Million USD | 78.733% |
Clever Leaves Holdings Inc. | 31.24 Million USD | 12.47% |
Lifecore Biomedical, Inc. | 273.7 Million USD | 90.008% |
PainReform Ltd. | 9.93 Million USD | -175.397% |
Cosmos Health Inc. | 66.29 Million USD | 58.75% |
Avadel Pharmaceuticals plc | 261.12 Million USD | 89.527% |
TherapeuticsMD, Inc. | 43.3 Million USD | 36.856% |
Embecta Corp. | 1.21 Billion USD | 97.748% |
Regencell Bioscience Holdings Limited | 8.43 Million USD | -224.085% |
Talphera, Inc. | 20.39 Million USD | -34.087% |
Pacira BioSciences, Inc. | 1.57 Billion USD | 98.263% |
Incannex Healthcare Limited | 17.04 Million USD | -60.421% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -106.431% |
Shineco, Inc. | 84.17 Million USD | 67.513% |
Procaps Group, S.A. | 460.18 Million USD | 94.057% |
ANI Pharmaceuticals, Inc. | 904.42 Million USD | 96.976% |
Aquestive Therapeutics, Inc. | 57.41 Million USD | 52.372% |
Lantheus Holdings, Inc. | 1.65 Billion USD | 98.344% |
Alvotech | 950.09 Million USD | 97.122% |
Hempacco Co., Inc. | 18.04 Million USD | -51.565% |
Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 93.267% |
Bright Green Corporation | 17.4 Million USD | -57.139% |
Esperion Therapeutics, Inc. | 205.79 Million USD | 86.712% |
Kamada Ltd. | 351.96 Million USD | 92.23% |
Indivior PLC | 1.95 Billion USD | 98.598% |
Evoke Pharma, Inc. | 7.06 Million USD | -286.882% |
Flora Growth Corp. | 23.62 Million USD | -15.749% |
Cyclo Therapeutics, Inc. | 13.24 Million USD | -106.431% |
Evolus, Inc. | 188.99 Million USD | 85.531% |
HUTCHMED (China) Limited | 1.27 Billion USD | 97.863% |
Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 98.192% |
Akanda Corp. | 8.83 Million USD | -209.355% |